The University of Chicago Header Logo

Susan L. Cohn

InstitutionUniversity of Chicago
AddressChicago IL 60637
Phone+1 (773) 702-2571
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Our long-term research interest is to improve the outcome for children with neuroblastoma. We are conducting laboratory-based research focused on understanding the cellular pathways that drive clinically aggressive neuroblastoma growth in order to identify actionable mutations that can be targeted and tested in clinical trials. We have an active collaboration with Drs. Chuan He and Lucy Godley investigating the epigenetic landscape of neuroblastoma. We are also collaborating with Dr. Sam Volchenboum and Dr. Robert Grossman to build an International Neuroblastoma Risk Group (INRG) Data Commons that contain phenotype data on a large cohort of neuroblastoma patients diagnosed around the world. The database was built with technology that allows connections with other databases that contain clinical and genomic information on patients with neuroblastoma diagnosed around the world. These data are available to investigators for data mining studies. Currently, clinical information on >20,000 patients with neuroblastoma are included in the INRG Data Commons. More than 20 research projects have been performed, and many of which would not have been possible with smaller patient cohorts.

    Collapse Biography 
    Collapse education and training
    Northwestern University, Evanston, IllinoinsBA1976Biology
    University of Illinois Medical School, Chicago, IllinoisMD1980
    Michael Reese Hospital and Medical Center, Chicago, Illinois1984Resident in Pediatrics
    Northwestern University, Chicago, Illinois1987Fellow in Pediatric Hematology/Oncology
    Collapse awards and honors
    2014Senior Faculty Scholar in the Bucksbaum Institute for Clinical Excellence, University of Chicago
    2012Association for Women in Science (AWIS) Chicago Innovator Award
    2012 - 2015Treasurer, American Society of Clinical Oncology
    2012Pritzker Scholar, University of Chicago
    2016American Society of Clinical Oncology Pediatric Oncology Award
    2016Fellow of the American Society of Clinical Oncology (FASCO)
    2018The Samuel Spector Award for Mentorship, Department of Pediatrics, University of Chicago
    2019AACR-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research , University of Chicago

    Collapse Research 
    Collapse research activities and funding
         (Volchenboum, S.L.)Jan 1, 2022 - Dec 3, 2025
    Innovation in Cancer Informatics
    GEARBOx - a multisite clinical trial matching tool for children with relapsed or refractory cancer
    Role Description: Project Goal: The University of Chicago’s Pediatric Cancer Data Commons (PCDC) team has built a platform called GEARBOx (Genomic Eligibility Algorithm at Relapse for Better Outcomes) that enables clinicians to match their acute myelogenous leukemia (AML) patients with open clinical trials for relapsed or refractory disease. In this grant, GEARBOx will be expanded to several other types of pediatric cancer and more efficient ways to extract criteria from trials using natural language processing will be developed. Connections to third parties, such as Foundation Medicine, Inc, will also be established to facilitate the automatic import of genomic biomarkers for faster and more accurate trial matching

    R21-CA259771     (Skapek, S)Apr 2, 2021 - Mar 31, 2023
    Identifying neuroblastoma drivers and bringing them to the clinic
    Role Description: Project Goals: The goal of this project is to identify drivers of aggressive neuroblastoma by integrating copy number and expression analysis. A second aim is to perform functional validation of in silico hits. Specific Aims: 1. To uncover oncogenic drivers and tumor suppressors in neuroblastoma by using iExCN, a Bayesian-based, intregrative analysis algorithm; 2. To experimentally validate iExCN-predicted drivers and tumor suppressors in a panel neuroblastoma cell lines and PDX models; 3. To explore how CNVs and expression of iExCN genes correlate with clinical variables to improve risk stratification models and guide therapy for children with neuroblastoma.

         (Cohn, S.L.)Jul 1, 2020 - Jun 30, 2022
    Hyundai Hope on Wheels
    Targeting DNA Double Strand Break (DSB) Repair Pathways Neuroblastoma
    Role Description: Project Goals: The overall goal of this study is to target proteins that promote efficient DNA damage repair in neuroblastoma to abrogate treatment resistance and improve the outcome of children with high-risk. Specific Aims: 1) To functionally characterize how MELK, EZH2, and MYCN mediate competent HR DSB repair. 2) To investigate the activity of PARP inhibitors in neuroblastoma cells with HR deficiency due to MELK, EZH2, or MYCN inhibition and treatment resistance in neuroblastoma cells:

         (Volchenboum, S.L.)Jul 1, 2019 - Jun 30, 2022
    St. Baldrick's Foundation
    Pediatric Cancer Data Commons
    Role Description: Project Goals: The goal of this St. Baldrick’s Consortium Grant is to develop a comprehensive Pediatric Cancer Data Commons to advance pediatric oncology research by harmonizing, collecting, storing, and sharing large amounts of clinical trials data from studies of children with cancer. Specific Aims: 1) Profile available sources of pediatric oncology clinical data and current data standards for pediatric cancer. 2) Establish a data dictionary for pediatric cancer clinical data and harmonize existing data sets. 3) Provide cohort discovery, data access tools and processes, and education and training to the pediatric oncology community.

         Dec 31, 2017 - Dec 30, 2019
    Hyundai Hope on Wheels
    MELK, A New Therapeutic Target for Neuroblastoma
    Role: Principal Investigator

         Oct 1, 2017 - Sep 30, 2019
    Alex's Lemonade Stand Foundation
    Genome-Wide 5hmC Profiling of Neuroblastoma Tumors and Patient Cell-free DNA
    Role: Principal Investigator

    UL1TR002389     (JACOBS, JOSHUA J;KIM, KAREN E;SOLWAY, JULIAN)Sep 6, 2017 - Jun 30, 2027
    The Institute for Translational Medicine
    Role: Co-Investigator

    R21CA173297     (COHN, SUSAN L.)Jul 1, 2013 - Jun 30, 2015
    Mechanisms of Pancreatic Cancer Inhibition by SPARC
    Role: Principal Investigator

    R21NS080120     (COHN, SUSAN L.)Mar 1, 2013 - Feb 28, 2015
    Mechanism of SPARC peptide FSEC inhibition of angiogenesis in neuroblastoma
    Role: Principal Investigator

    R01NS049814     (COHN, SUSAN L)Jul 1, 2004 - Apr 30, 2009
    The Role of SPARC in Neuroblastoma Angiogenesis
    Role: Principal Investigator

    R01CA074824     (COHN, SUSAN L)Aug 1, 1997 - May 31, 2002
    Role: Principal Investigator

    R03HS007846     (COHN, SUSAN E)Sep 30, 1992 - Sep 29, 1994
    Role: Principal Investigator

    R29CA051061     (COHN, SUSAN L)Jul 1, 1990 - Jun 30, 1995
    Role: Principal Investigator

    U10CA007431     (COHN, SUSAN L)Dec 1, 1978 - Dec 31, 2002
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kaye EC, Smith J, Zhou Y, Bagatell R, Baker JN, Cohn SL, Diller LR, Glade Bender JL, Granger MM, Marachelian A, Park JR, Rosenberg AR, Shusterman S, Twist CJ, Mack JW. Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study. Cancer. 2023 Dec 15. PMID: 38100619.
      Citations:    Fields:    
    2. Cohn SL, Land V, Link MP, Grier HE. In Memoriam: Sharon B. Murphy, MD (1943-2023). Pediatr Blood Cancer. 2024 Feb; 71(2):e30797. PMID: 38037198.
      Citations:    Fields:    
    3. Vayani OR, Kaufman ME, Moore K, Chennakesavalu M, TerHaar R, Chaves G, Chlenski A, He C, Cohn SL, Applebaum MA. Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma. Pediatr Blood Cancer. 2024 Jan; 71(1):e30735. PMID: 37859597; PMCID: PMC10842006.
      Citations: 1     Fields:    Translation:Humans
    4. Vayani OR, Kaufman ME, Moore K, Chennakesavalu M, TerHaar R, Chaves G, Chlenski A, He C, Cohn SL, Applebaum MA. Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma. bioRxiv. 2023 Sep 01. PMID: 37693610; PMCID: PMC10491182.
    5. Chennakesavalu M, Pudela C, Applebaum MA, Lee SM, Che Y, Naranjo A, Park JR, Volchenboum SL, Henderson TO, Cohn SL, Desai AV. Persistence of Racial and Ethnic Disparities in Risk and Survival for Patients with Neuroblastoma over Two Decades. EJC Paediatr Oncol. 2023 Dec; 2. PMID: 38213818; PMCID: PMC10783478.
    6. Kaufman ME, Vayani OR, Moore K, Chlenski A, Wu T, Chavez G, Lee SM, Desai AV, He C, Cohn SL, Applebaum MA. T-cell inflammation is prognostic of survival in patients with high-risk neuroblastoma enriched for an adrenergic signature. bioRxiv. 2023 Jun 28. PMID: 37425883; PMCID: PMC10326980.
    7. Bender HG, Irwin MS, Hogarty MD, Castleberry R, Maris JM, Kao PC, Zhang FF, Naranjo A, Cohn SL, London WB. Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification. J Clin Oncol. 2023 06 10; 41(17):3149-3159. PMID: 37098238; PMCID: PMC10256433.
      Citations: 3     Fields:    Translation:Humans
    8. Desai AV, Elmuti L, Cahaney C, De Guzman RM, Streby KA, Cohn SL. Multimodality treatment for recurrent neuroblastoma in the central nervous system. Pediatr Blood Cancer. 2023 04; 70(4):e30227. PMID: 36720647.
      Citations:    Fields:    Translation:Humans
    9. Friedman DN, Goodman PJ, Leisenring WM, Diller LR, Cohn SL, Howell RM, Smith SA, Tonorezos ES, Wolden SL, Neglia JP, Ness KK, Gibson TM, Nathan PC, Weil BR, Robison LL, Oeffinger KC, Armstrong GT, Sklar CA, Henderson TO. Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2023 03 10; 41(8):1565-1576. PMID: 36525618; PMCID: PMC10043581.
      Citations: 7     Fields:    Translation:Humans
    10. Campbell DM, Cowlings PD, Tholanah M, Robinson MJ, Graham G, Aseru S, Cohn SE, Bar KJ, Connick E, Mngqbisa R, Scully EP, Stockman JK, Gianella S, Dubé K. A Community Call to Action to Prioritize Inclusion and Enrollment of Women in HIV Cure-related Research. J Acquir Immune Defic Syndr. 2022 12 15; 91(5):e12-e14. PMID: 36083494; PMCID: PMC9646409.
      Citations: 1     Fields:    Translation:Humans
    11. Hains AE, Uppal S, Cao JZ, Salwen HR, Applebaum MA, Cohn SL, Godley LA. MYCN and HIF-1 directly regulate TET1 expression to control 5-hmC gains and enhance neuroblastoma cell migration in hypoxia. Epigenetics. 2022 12; 17(13):2056-2074. PMID: 35942521; PMCID: PMC9665154.
      Citations:    Fields:    Translation:HumansCells
    12. Desai AV, Gilman AL, Ozkaynak MF, Naranjo A, London WB, Tenney SC, Diccianni M, Hank JA, Parisi MT, Shulkin BL, Smith M, Moscow JA, Shimada H, Matthay KK, Cohn SL, Maris JM, Bagatell R, Sondel PM, Park JR, Yu AL. Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. J Clin Oncol. 2022 12 10; 40(35):4107-4118. PMID: 35839426; PMCID: PMC9746736.
      Citations: 9     Fields:    Translation:Humans
    13. Desai AV, Applebaum MA, Karrison TG, Oppong A, Yuan C, Berg KR, MacQuarrie K, Sokol E, Hall AG, Pinto N, Wolfe I, Mody R, Shusterman S, Smith V, Foster JH, Nassin M, LaBelle JL, Bagatell R, Cohn SL. Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977. PMID: 35665495; PMCID: PMC10764281.
      Citations: 4     Fields:    Translation:Humans
    14. Cohn SL, Pearson ADJ. Rethinking high-risk neuroblastoma treatment. Pediatr Blood Cancer. 2022 08; 69(8):e29730. PMID: 35441788.
      Citations: 1     Fields:    Translation:Humans
    15. LaFond CM, Yost A, Lankin K, Kilaru M, Cohn SL. The Experience of Children With Neuroblastoma and Their Parents During Single-Room Isolation for 131I-Metaiodobenzylguanidine Therapy: A Qualitative Descriptive Study. J Pediatr Hematol Oncol Nurs. 2022 Sep-Oct; 39(5):304-316. PMID: 36129889.
      Citations:    Fields:    Translation:Humans
    16. Mayampurath A, Ramesh S, Michael D, Liu L, Feinberg N, Granger M, Naranjo A, Cohn SL, Volchenboum SL, Applebaum MA. Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. JCO Clin Cancer Inform. 2021 12; 5:1181-1188. PMID: 34882497; PMCID: PMC8812615.
      Citations: 3     Fields:    Translation:Humans
    17. Plana A, Furner B, Palese M, Dussault N, Birz S, Graglia L, Kush M, Nicholson J, Rasche M, Bisogno G, Reinhardt D, Frazier AL, Janeway K, S Hawkins D, Kolb EA, Cohn SL, Pearson ADJ, Volchenboum SL, Hecker-Nolting S, Gaspar N, Zwaan CM, Koscielniak E. Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. JCO Clin Cancer Inform. 2021 09; 5:1034-1043. PMID: 34662145.
      Citations: 11     Fields:    Translation:Humans
    18. Masters MC, Cohn SE. Two-drug HIV regimens: more data still needed. Lancet HIV. 2021 08; 8(8):e454-e455. PMID: 34358493.
      Citations:    Fields:    Translation:HumansCells
    19. Kawano A, Hazard FK, Chiu B, Naranjo A, LaBarre B, London WB, Hogarty MD, Cohn SL, Maris JM, Park JR, Gastier-Foster JM, Ikegaki N, Shimada H. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. 2021 08 01; 45(8):1075-1081. PMID: 33739795; PMCID: PMC8217390.
      Citations: 6     Fields:    Translation:Humans
    20. Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, Ramirez NC, Pfau R, Reshmi S, Wagner E, Nuchtern J, Asgharzadeh S, Shimada H, Maris JM, Bagatell R, Park JR, Hogarty MD. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. J Clin Oncol. 2021 10 10; 39(29):3229-3241. PMID: 34319759; PMCID: PMC8500606.
      Citations: 87     Fields:    Translation:Humans
    21. DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A, Czarnecki S, Goodarzian F, Berkovich R, Shimada H, Villablanca JG, Vo KT, Pinto N, Mosse YP, Maris JM, Shusterman S, Cohn SL, Goldsmith KC, Weiss B, Yanik GA, Twist CJ, Irwin MS, Haas-Kogan DA, Park JR, Marachelian A, Matthay KK. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol. 2021 11 01; 39(31):3506-3514. PMID: 34270348; PMCID: PMC8547934.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    22. Balyasny S, Lee SM, Desai AV, Volchenboum SL, Naranjo A, Park JR, London WB, Cohn SL, Applebaum MA. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 07 01; 4(7):e2116248. PMID: 34236408; PMCID: PMC8267607.
      Citations: 1     Fields:    Translation:Humans
    23. Bao R, Spranger S, Hernandez K, Zha Y, Pytel P, Luke JJ, Gajewski TF, Volchenboum SL, Cohn SL, Desai AV. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021 07; 9(7). PMID: 34272305; PMCID: PMC8287618.
      Citations: 15     Fields:    Translation:Humans
    24. Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 04 15; 27(8):2179-2189. PMID: 33504555; PMCID: PMC8046731.
      Citations: 63     Fields:    Translation:HumansCTClinical Trials
    25. Moreno L, Guo D, Irwin MS, Berthold F, Hogarty M, Kamijo T, Morgenstern D, Pasqualini C, Ash S, Potschger U, Ladenstein R, Valteau-Couanet D, Cohn SL, Pearson ADJ, London WB. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2021 03; 68(3):e28794. PMID: 33205902.
      Citations: 14     Fields:    Translation:Humans
    26. Liang WH, Federico SM, London WB, Naranjo A, Irwin MS, Volchenboum SL, Cohn SL. Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. JCO Clin Cancer Inform. 2020 10; 4:895-905. PMID: 33058692; PMCID: PMC7608590.
      Citations: 28     Fields:    Translation:Humans
    27. Sokol E, Desai AV, Applebaum MA, Valteau-Couanet D, Park JR, Pearson ADJ, Schleiermacher G, Irwin MS, Hogarty M, Naranjo A, Volchenboum S, Cohn SL, London WB. Reply to K. Beiske et al. J Clin Oncol. 2020 11 01; 38(31):3720-3721. PMID: 32931402.
      Citations:    Fields:    Translation:Humans
    28. Ambros IM, Gross N, Beiske K, Bown N, Caron H, Defferrari R, Jeison M, Kogner P, Lunec J, Mazzocco K, Van Roy N, Janousek D, Pribill I, Glogova E, Attiyeh EF, Hogarty MD, Monclair TF, Holmes K, Castel V, Tweddle DA, Park JR, Cohn S, Ladenstein R, Beck-Popovic M, De Bernardi B, Pearson ADJ, Ambros PF, Tonini GP, Pötschger U, Mosseri V, Berbegall AP, Bénard J, Combaret V, Couturier J, Delattre O, Marques B, Martinsson T, Noguera R, Schleiermacher G, Valent A, Villamon E, Valteau-Couanet D, Michon J. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. J Clin Oncol. 2020 11 01; 38(31):3685-3697. PMID: 32903140; PMCID: PMC7605396.
      Citations: 6     Fields:    Translation:HumansCells
    29. Barr EK, Laurie K, Wroblewski K, Applebaum MA, Cohn SL. Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients. Pediatr Blood Cancer. 2020 10; 67(10):e28390. PMID: 32710697; PMCID: PMC7722196.
      Citations: 3     Fields:    Translation:Humans
    30. Moroz V, Machin D, Hero B, Ladenstein R, Berthold F, Kao P, Obeng Y, Pearson ADJ, Cohn SL, London WB. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2020 08; 67(8):e28359. PMID: 32472746.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    31. Gerstle K, Siddiqui A, Schulte JJ, Cohn SL. Paraneoplastic opsoclonus myoclonus syndrome associated with inflammatory myofibroblastic tumor in a pediatric patient. Pediatr Blood Cancer. 2020 08; 67(8):e28218. PMID: 32472953; PMCID: PMC8627193.
      Citations:    Fields:    Translation:Humans
    32. Mack JW, Uno H, Twist CJ, Bagatell R, Rosenberg AR, Marachelian A, Granger MM, Glade Bender J, Baker JN, Park JR, Cohn SL, Fernandez JH, Diller LR, Shusterman S. Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. J Pain Symptom Manage. 2020 10; 60(4):782-789. PMID: 32360991; PMCID: PMC7523916.
      Citations: 7     Fields:    Translation:Humans
    33. Sokol E, Desai AV, Applebaum MA, Valteau-Couanet D, Park JR, Pearson ADJ, Schleiermacher G, Irwin MS, Hogarty M, Naranjo A, Volchenboum S, Cohn SL, London WB. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. J Clin Oncol. 2020 06 10; 38(17):1906-1918. PMID: 32315273; PMCID: PMC7280049.
      Citations: 26     Fields:    Translation:Humans
    34. Applebaum MA, Barr EK, Karpus J, West-Szymanski DC, Oliva M, Sokol EA, Zhang S, Zhang Z, Zhang W, Chlenski A, Salwen HR, Wilkinson E, Dobratic M, Grossman RL, Godley LA, Stranger BE, He C, Cohn SL. 5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma. Clin Cancer Res. 2020 03 15; 26(6):1309-1317. PMID: 31852832; PMCID: PMC7073281.
      Citations: 15     Fields:    Translation:HumansCells
    35. Kang HJ, Yalon-Oren M, Marshall LV, Pappo A, Laetsch TW, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N, Geoerger B, Vezina C, Petrilli AS, Ebinger M, Toporski J. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020 01; 21(1):121-133. PMID: 31812554.
      Citations: 103     Fields:    Translation:HumansCTClinical Trials
    36. Masters MC, Krueger KM, Williams JL, Morrison L, Cohn SE. Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States. Expert Rev Clin Pharmacol. 2019 Dec; 12(12):1129-1143. PMID: 31774001; PMCID: PMC7073258.
      Citations: 6     Fields:    Translation:Humans
    37. Mack JW, Cronin AM, Uno H, Shusterman S, Twist CJ, Bagatell R, Rosenberg A, Marachelian A, Granger MM, Glade Bender J, Baker JN, Park J, Cohn SL, Levine A, Taddei S, Diller LR. Unrealistic parental expectations for cure in poor-prognosis childhood cancer. Cancer. 2020 01 15; 126(2):416-424. PMID: 31584705; PMCID: PMC7523918.
      Citations: 18     Fields:    Translation:Humans
    38. Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 08 27; 322(8):746-755. PMID: 31454045; PMCID: PMC6714031.
      Citations: 111     Fields:    Translation:Humans
    39. Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 12 01; 37(34):3243-3255. PMID: 31386611; PMCID: PMC6881103.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    40. Kemp CG, Lipira L, Huh D, Nevin PE, Turan JM, Simoni JM, Cohn SE, Bahk M, Berzins B, Andrasik M, Mugavero MJ, Rao D. HIV stigma and viral load among African-American women receiving treatment for HIV. AIDS. 2019 07 15; 33(9):1511-1519. PMID: 31259767; PMCID: PMC6621603.
      Citations: 29     Fields:    Translation:Humans
    41. Applebaum MA, Barr EK, Karpus J, Nie J, Zhang Z, Armstrong AE, Uppal S, Sukhanova M, Zhang W, Chlenski A, Salwen HR, Wilkinson E, Dobratic M, Grossman R, Godley LA, Stranger BE, He C, Cohn SL. 5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype. JCO Precis Oncol. 2019; 3. PMID: 31179414; PMCID: PMC6553657.
      Citations: 13     Fields:    
    42. Braunstein SE, London WB, Kreissman SG, Villablanca JG, Davidoff AM, DeSantes K, Castleberry RP, Murray K, Diller L, Matthay K, Cohn SL, Shulkin B, von Allmen D, Parisi MT, Van Ryn C, Park JR, La Quaglia MP, Haas-Kogan DA. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatr Blood Cancer. 2019 07; 66(7):e27736. PMID: 30968542; PMCID: PMC7281832.
      Citations: 4     Fields:    Translation:Humans
    43. Chlenski A, Park C, Dobratic M, Salwen HR, Budke B, Park JH, Miller R, Applebaum MA, Wilkinson E, Nakamura Y, Connell PP, Cohn SL. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. Mol Cancer Ther. 2019 03; 18(3):507-516. PMID: 30674566; PMCID: PMC6398941.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    44. Naranjo A, Irwin MS, Hogarty MD, Cohn SL, Park JR, London WB. Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. JCO Clin Cancer Inform. 2018 12; 2:1-15. PMID: 30652588; PMCID: PMC6421832.
      Citations: 12     Fields:    Translation:Humans
    45. Morgenstern DA, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Park JR, Pearson AD, Schleiermacher G, Valteau-Couanet D, London WB, Irwin MS, Moreno L. The challenge of defining "ultra-high-risk" neuroblastoma. Pediatr Blood Cancer. 2019 04; 66(4):e27556. PMID: 30479064.
      Citations: 29     Fields:    Translation:Humans
    46. Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 01 10; 37(2):115-124. PMID: 30444686; PMCID: PMC6325354.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    47. Sokol EA, Engelmann R, Kang W, Pinto N, Starkey A, Lai H, Nadel H, Shulkin BL, Pu Y, Appelbaum D, Yanik GA, Cohn SL, Armato SG, Volchenboum S. Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer. 2018 12; 65(12):e27417. PMID: 30198643; PMCID: PMC6317352.
      Citations: 2     Fields:    Translation:Humans
    48. DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith K, Granger MM, Weiss B, Park JR, Macy ME, Cohn SL, Yanik G, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2018 12 15; 24(24):6142-6149. PMID: 30093449; PMCID: PMC6295246.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    49. Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A, Van Ryn C, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Ikegaki N, Shimada H. MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget. 2018 Jan 19; 9(5):6416-6432. PMID: 29464082; PMCID: PMC5814222.
      Citations: 17     Fields:    
    50. Nassin ML, Nicolaou E, Gurbuxani S, Cohn SL, Cunningham JM, LaBelle JL. Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy. Biol Blood Marrow Transplant. 2018 03; 24(3):452-459. PMID: 29191664.
      Citations: 8     Fields:    Translation:Humans
    51. de Alarcon PA, Matthay KK, London WB, Naranjo A, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health. 2018 01; 2(1):25-34. PMID: 29376112; PMCID: PMC5783315.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    52. Erbe AK, Wang W, Carmichael L, Kim K, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM, Mendonça EA. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res. 2018 01 01; 24(1):189-196. PMID: 28972044; PMCID: PMC5754221.
      Citations: 29     Fields:    Translation:HumansCells
    53. Hungate EA, Applebaum MA, Skol AD, Vaksman Z, Diamond M, McDaniel L, Volchenboum SL, Stranger BE, Maris JM, Diskin SJ, Onel K, Cohn SL. Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. J Natl Cancer Inst. 2017 10 01; 109(10). PMID: 29117357; PMCID: PMC6279278.
      Citations: 13     Fields:    Translation:Humans
    54. Tran L, Fitzpatrick C, Cohn SL, Pytel P. Composite tumor with pheochromocytoma and immature neuroblastoma: report of two cases with cytogenetic analysis and discussion of current terminology. Virchows Arch. 2017 Oct; 471(4):553-557. PMID: 28864906; PMCID: PMC5614909.
      Citations: 5     Fields:    Translation:Humans
    55. Cohn SE. Women in HIV trials: improving adherence and outcomes. Lancet HIV. 2017 12; 4(12):e530-e531. PMID: 28729157.
      Citations: 1     Fields:    Translation:Humans
    56. Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 01; 35(22):2580-2587. PMID: 28471719; PMCID: PMC5676955.
      Citations: 113     Fields:    Translation:Humans
    57. Applebaum MA, Desai AV, Glade Bender JL, Cohn SL. Emerging and investigational therapies for neuroblastoma. Expert Opin Orphan Drugs. 2017; 5(4):355-368. PMID: 29062613; PMCID: PMC5649635.
      Citations: 14     
    58. Secola R, Marachelian A, Cohn SL, Toy B, Neville K, Granger M, Brentlinger A, Martin G. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy. J Pediatr Oncol Nurs. 2017 May/Jun; 34(3):160-172. PMID: 28061552; PMCID: PMC7523913.
      Citations: 1     Fields:    Translation:Humans
    59. Volchenboum SL, Cox SM, Heath A, Resnick A, Cohn SL, Grossman R. Data Commons to Support Pediatric Cancer Research. Am Soc Clin Oncol Educ Book. 2017; 37:746-752. PMID: 28561664.
      Citations: 18     Fields:    Translation:Humans
    60. Chen L, Humphreys A, Turnbull L, Bellini A, Schleiermacher G, Salwen H, Cohn SL, Bown N, Tweddle DA. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse. Oncotarget. 2016 Dec 27; 7(52):87301-87311. PMID: 27888620; PMCID: PMC5349989.
      Citations: 12     Fields:    Translation:HumansCells
    61. Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, Pinto N, Volchenboum SL, Park JR, Naranjo A, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 02; 72:177-185. PMID: 28033528; PMCID: PMC5258837.
      Citations: 32     Fields:    Translation:HumansCells
    62. Chlenski A, Dobratic M, Salwen HR, Applebaum M, Guerrero LJ, Miller R, DeWane G, Solomaha E, Marks JD, Cohn SL. Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids. Oncotarget. 2016 Nov 22; 7(47):77696-77706. PMID: 27776337; PMCID: PMC5363614.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    63. Applebaum MA, Jha AR, Kao C, Hernandez KM, DeWane G, Salwen HR, Chlenski A, Dobratic M, Mariani CJ, Godley LA, Prabhakar N, White K, Stranger BE, Cohn SL. Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. Oncotarget. 2016 Nov 22; 7(47):76816-76826. PMID: 27765905; PMCID: PMC5340231.
      Citations: 22     Fields:    Translation:HumansCells
    64. Sokol E, Huang E, Pytel P, Cohn SL, Pinto N. Rebound thymic hyperplasia following high dose chemotherapy and stem cell transplant in three neuroblastoma patients. Pediatr Blood Cancer. 2017 03; 64(3). PMID: 27663277.
      Citations: 1     Fields:    Translation:Humans
    65. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Nakagawara A, Shimada H, Matthay KK, Cohn SL, Pearson AD, Irwin MS, Simon T, Schleiermacher G. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016 09; 65:1-10. PMID: 27434878.
      Citations: 27     Fields:    Translation:Humans
    66. Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 08; 63(8):1349-56. PMID: 27092812; PMCID: PMC8992729.
      Citations: 33     Fields:    Translation:HumansCellsCTClinical Trials
    67. Pinto N, Mayfield JR, Raca G, Applebaum MA, Chlenski A, Sukhanova M, Bagatell R, Irwin MS, Little A, Rawwas J, Gosiengfiao Y, Cohn SL, Delattre O, Janoueix-Lerosey I, Lapouble E, Schleiermacher G. Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. Pediatr Blood Cancer. 2016 Jun; 63(6):1019-23. PMID: 26864375; PMCID: PMC5109976.
      Citations: 10     Fields:    Translation:Humans
    68. Bagatell R, Cohn SL. Genetic discoveries and treatment advances in neuroblastoma. Curr Opin Pediatr. 2016 Feb; 28(1):19-25. PMID: 26576010; PMCID: PMC4731097.
      Citations: 21     Fields:    Translation:HumansCells
    69. Marachelian A, Desai A, Balis F, Katzenstein H, Qayed M, Armstrong M, Neville KA, Cohn SL, Gunawan R, Lim AP, Smith MA, Smith LM, Bush M. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemother Pharmacol. 2016 Feb; 77(2):405-12. PMID: 26791869; PMCID: PMC4747995.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    70. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep 20; 33(27):3008-17. PMID: 26304901; PMCID: PMC4567703.
      Citations: 354     Fields:    Translation:Humans
    71. Cohn SL. A Selfless Act. J Clin Oncol. 2015 Nov 10; 33(32):3834-5. PMID: 26261250.
      Citations: 1     Fields:    Translation:Humans
    72. Darlington WS, Pinto N, Hecktman HM, Cohn SL, LaBelle JL. Stem Cell Transplant-Associated Wernicke Encephalopathy in a Patient with High-Risk Neuroblastoma. Pediatr Blood Cancer. 2015 Dec; 62(12):2232-4. PMID: 26174546.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    73. Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Shimada H. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study. Br J Cancer. 2015 Jun 30; 113(1):57-63. PMID: 26035700; PMCID: PMC4647535.
      Citations: 62     Fields:    Translation:Humans
    74. DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. PMID: 25695691; PMCID: PMC4470833.
      Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
    75. Applebaum MA, Henderson TO, Lee SM, Pinto N, Volchenboum SL, Cohn SL. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer. 2015 Jan; 62(1):128-33. PMID: 25251613; PMCID: PMC4237647.
      Citations: 25     Fields:    Translation:HumansPHPublic Health
    76. Teshiba R, Kawano S, Wang LL, He L, Naranjo A, London WB, Seeger RC, Gastier-Foster JM, Look AT, Hogarty MD, Cohn SL, Maris JM, Park JR, Shimada H. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group. Pediatr Dev Pathol. 2014 Nov-Dec; 17(6):441-9. PMID: 25207821; PMCID: PMC4340697.
      Citations: 18     Fields:    Translation:Humans
    77. Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014 Oct 01; 32(28):3169-76. PMID: 25154816; PMCID: PMC4171360.
      Citations: 71     Fields:    Translation:Humans
    78. Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014 Nov; 61(11):1932-9. PMID: 25044743.
      Citations: 18     Fields:    Translation:Humans
    79. Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, Bhattacharyya S, Wenger RH, Cohn SL, Nanduri J, Verma A, Prabhakar NR, Godley LA. TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma. Cell Rep. 2014 Jun 12; 7(5):1343-1352. PMID: 24835990; PMCID: PMC4516227.
      Citations: 89     Fields:    Translation:HumansCells
    80. London WB, Stephens D, Volchenboum SL, Hero B, Di Cataldo A, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson AD, Irwin MS, Morgenstern DA. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. J Clin Oncol. 2014 Apr 20; 32(12):1228-35. PMID: 24663047; PMCID: PMC4876342.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    81. Martin A, Schneiderman J, Helenowski IB, Morgan E, Dilley K, Danner-Koptik K, Hatahet M, Shimada H, Cohn SL, Kletzel M, Hijiya N. Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. Pediatr Blood Cancer. 2014 Aug; 61(8):1350-6. PMID: 24634399.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    82. Pinto N, Gamazon ER, Antao N, Myers J, Stark AL, Konkashbaev A, Im HK, Diskin SJ, London WB, Ludeman SM, Maris JM, Cox NJ, Cohn SL, Dolan ME. Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther. 2014 Jun; 95(6):644-52. PMID: 24549002; PMCID: PMC4029857.
      Citations: 5     Fields:    Translation:HumansCells
    83. Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, London WB, Pytel P, Maclean KH, Cohn SL. Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system. Mol Oncol. 2014 May; 8(3):669-78. PMID: 24560446; PMCID: PMC4004665.
      Citations: 20     Fields:    Translation:Humans
    84. Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). Pediatr Blood Cancer. 2014 Jun; 61(6):990-6. PMID: 24347462; PMCID: PMC5127168.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    85. Pinto N, Cipkala DA, Ladd PE, Pu Y, Cohn SL. Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretenoin alone or observation. Pediatr Blood Cancer. 2014 Jun; 61(6):1104-6. PMID: 24293072.
      Citations: 1     Fields:    Translation:Humans
    86. Armstrong AE, Dargart J, Reichek J, Walterhouse DO, Matossian D, Cohn RA, Gosiengfiao Y. Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis. Pediatr Blood Cancer. 2014 May; 61(5):949-50. PMID: 24273036.
      Citations: 3     Fields:    Translation:Humans
    87. Deyell RJ, Berthold F, Nagakawara A, Ambros PF, Monclair T, Cohn SL, Pearson AD, London WB, Matthay KK, Mossé YP. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014 Apr; 61(4):627-35. PMID: 24038992.
      Citations: 37     Fields:    Translation:HumansCells
    88. Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. Cancer. 2013 Oct 15; 119(20):3718-26. PMID: 23901000; PMCID: PMC4554323.
      Citations: 39     Fields:    Translation:HumansCells
    89. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Sep; 14(10):999-1008. PMID: 23890779; PMCID: PMC3963485.
      Citations: 140     Fields:    Translation:HumansCTClinical Trials
    90. Kirby C, Ambros PF, Billiter D, London WB, Mendonca E, Monclair T, Pearson AD, Cohn SL, Volchenboum SL. Development of an open-source, flexible framework for complex inter-institutional disparate data sharing and collaboration. AMIA Jt Summits Transl Sci Proc. 2013; 2013:103. PMID: 24303312.
      Citations: 1     
    91. Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KK. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. J Nucl Med. 2013 Apr; 54(4):541-8. PMID: 23440556; PMCID: PMC5503147.
      Citations: 68     Fields:    Translation:Humans
    92. Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant. 2013 Jul; 48(7):947-52. PMID: 23334272; PMCID: PMC3638062.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    93. Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, Mattay KM, Hogarty M, COG Neuroblastoma Committee. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013 Jun; 60(6):985-93. PMID: 23255319.
      Citations: 159     Fields:    Translation:Humans
    94. Gamazon ER, Pinto N, Konkashbaev A, Im HK, Diskin SJ, London WB, Maris JM, Dolan ME, Cox NJ, Cohn SL. Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. J Natl Cancer Inst. 2013 Feb 20; 105(4):302-9. PMID: 23243203; PMCID: PMC3691940.
      Citations: 17     Fields:    Translation:Humans
    95. Sokol E, Haut PR, Gosiengfiao Y, Feinstein K, Pytel P, Cohn SL. Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone. Pediatr Blood Cancer. 2013 Mar; 60(3):512-4. PMID: 23129137.
      Citations:    Fields:    Translation:Humans
    96. Nuchtern JG, London WB, Barnewolt CE, Naranjo A, McGrady PW, Geiger JD, Diller L, Schmidt ML, Maris JM, Cohn SL, Shamberger RC. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg. 2012 Oct; 256(4):573-80. PMID: 22964741; PMCID: PMC5665168.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    97. Morales La Madrid A, Nall MB, Ouyang K, Minor A, Raca G, Kent P, Miller I, Schleiermacher G, Janoueix-Lerosey I, Cohn SL. Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression. Pediatr Blood Cancer. 2013 Feb; 60(2):332-5. PMID: 22997192.
      Citations: 3     Fields:    Translation:Humans
    98. Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini GP, Fischer M, Ambros I, Monclair T, Matthay KK, Ambros P, Cohn SL, Pearson AD, Schleiermacher G. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer. 2012 Oct 09; 107(8):1418-22. PMID: 22976801; PMCID: PMC3494425.
      Citations: 74     Fields:    Translation:HumansCells
    99. Morales La Madrid A, La Madrid AM, Campbell N, Smith S, Cohn SL, Salgia R. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 2012 Sep; 7(3):199-210. PMID: 22968692.
      Citations: 16     Fields:    Translation:HumansCells
    100. Ostler KR, Yang Q, Looney TJ, Zhang L, Vasanthakumar A, Tian Y, Kocherginsky M, Raimondi SL, DeMaio JG, Salwen HR, Gu S, Chlenski A, Naranjo A, Gill A, Peddinti R, Lahn BT, Cohn SL, Godley LA. Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma. Cancer Res. 2012 Sep 15; 72(18):4714-23. PMID: 22815530; PMCID: PMC3445765.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    101. Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, Jarzembowski JA, Joshi VV, Navarro S, Peuchmaur M, Shimada H. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatr Blood Cancer. 2013 Mar; 60(3):363-70. PMID: 22744966; PMCID: PMC3397468.
      Citations: 13     Fields:    Translation:Humans
    102. London WB, Schmidt ML, Brodeur GM, Shimada H, Thorner P, Collins MH, Tagge E, Adkins S, Reynolds CP, Murray K, Lavey RS, Matthay KK, Castleberry R, Maris JM, Cohn SL, Strother DR. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012 May 20; 30(15):1842-8. PMID: 22529259; PMCID: PMC3383182.
      Citations: 72     Fields:    Translation:HumansCTClinical Trials
    103. Zage PE, Louis CU, Cohn SL. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. Pediatr Blood Cancer. 2012 Jul 01; 58(7):1099-105. PMID: 22378620; PMCID: PMC4104176.
      Citations: 11     Fields:    Translation:Humans
    104. Morales La Madrid A, Volchenboum S, Gastier-Foster JM, Pyatt R, Liu D, Pytel P, Lavarino C, Rodriguez E, Cohn SL. Locoregional MYCN-amplified neuroblastoma. Pediatr Blood Cancer. 2012 Oct; 59(4):736-8. PMID: 22213566.
      Citations:    Fields:    Translation:Humans
    105. Kakodkar NC, Peddinti RR, Tian Y, Guerrero LJ, Chlenski A, Yang Q, Salwen HR, Maitland ML, Cohn SL. Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. Pediatr Blood Cancer. 2012 Oct; 59(4):642-7. PMID: 22147414.
      Citations: 15     Fields:    Translation:AnimalsCells
    106. Angelini P, London WB, Cohn SL, Pearson AD, Matthay KK, Monclair T, Ambros PF, Shimada H, Leuschner I, Peuchmaur M, Irwin MS, Baruchel S. Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project. Eur J Cancer. 2012 May; 48(8):1185-91. PMID: 22137163.
      Citations: 8     Fields:    Translation:Humans
    107. Cohn S. Advances in the treatment of neuroblastoma. Clin Adv Hematol Oncol. 2011 Nov; 9(11):865-7. PMID: 22252619.
      Citations:    Fields:    Translation:Humans
    108. Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KK. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Nov 20; 29(33):4351-7. PMID: 22010014; PMCID: PMC3221519.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    109. London WB, Schmidt ML, DuBois SG, Monclair TF, Nakagawara A, De Bernardi B, Ambros PF, Pearson AD, Cohn SL, Matthay KK, Taggart DR. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011 Nov 20; 29(33):4358-64. PMID: 21969516; PMCID: PMC3221520.
      Citations: 25     Fields:    Translation:Humans
    110. Villablanca JG, London WB, Naranjo A, McGrady P, Ames MM, Reid JM, McGovern RM, Buhrow SA, Jackson H, Stranzinger E, Kitchen BJ, Sondel PM, Parisi MT, Shulkin B, Yanik GA, Cohn SL, Reynolds CP. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res. 2011 Nov 01; 17(21):6858-66. PMID: 21908574; PMCID: PMC3207022.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    111. Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C, Murray J, Flemming CL, Smith J, Fletcher JI, Gherardi S, Kwek CK, Russell AJ, Valli E, London WB, Buxton AB, Ashton LJ, Sartorelli AC, Cohn SL, Schwab M, Marshall GM, Perini G, Norris MD. ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst. 2011 Aug 17; 103(16):1236-51. PMID: 21799180; PMCID: PMC3156802.
      Citations: 53     Fields:    Translation:HumansAnimalsCells
    112. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, Matthay KK. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011 Aug 20; 29(24):3286-92. PMID: 21768459; PMCID: PMC3158599.
      Citations: 133     Fields:    Translation:Humans
    113. McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, Giammarile F, Schmidt M, Shulkin BL, Matthay KK, Lewington VJ, Sarnacki S, Hero B, Kaneko M, London WB, Pearson AD, Cohn SL, Monclair T, International Neuroblastoma Risk Group Project, Brisse HJ. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011 Oct; 261(1):243-57. PMID: 21586679.
      Citations: 131     Fields:    Translation:Humans
    114. Morales La Madrid A, Rubin CM, Kohrman M, Pytel P, Cohn SL. Opsoclonus-myoclonus and anti-Hu positive limbic encephalitis in a patient with neuroblastoma. Pediatr Blood Cancer. 2012 Mar; 58(3):472-4. PMID: 21480475.
      Citations: 6     Fields:    Translation:Humans
    115. Kakodkar NC, Peddinti R, Kletzel M, Tian Y, Guerrero LJ, Undevia SD, Geary D, Chlenski A, Yang Q, Salwen HR, Cohn SL. The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth. Pediatr Blood Cancer. 2011 Jan; 56(1):164-7. PMID: 20860039; PMCID: PMC4116189.
      Citations: 6     Fields:    Translation:HumansCells
    116. Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, Kretschmar C, Cohn SL. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Jan 10; 29(2):208-13. PMID: 21115869; PMCID: PMC3058276.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    117. Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V, Ladenstein R, De Bernardi B, Berthold F, Matthay KK, Monclair T, Ambros PF, Pearson AD, Cohn SL, London WB, Rubie H. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2011 Mar; 47(4):561-71. PMID: 21112770.
      Citations: 39     Fields:    Translation:Humans
    118. Henderson TO, Bhatia S, Pinto N, London WB, McGrady P, Crotty C, Sun CL, Cohn SL. Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Jan 01; 29(1):76-82. PMID: 21098321; PMCID: PMC3055862.
      Citations: 55     Fields:    Translation:Humans
    119. Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20; 28(33):4969-75. PMID: 20921469; PMCID: PMC3020698.
      Citations: 124     Fields:    Translation:HumansCTClinical Trials
    120. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK, Children’s Oncology Group. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1313-23. PMID: 20879880; PMCID: PMC2993160.
      Citations: 107     Fields:    Translation:HumansCTClinical Trials
    121. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1324-34. PMID: 20879881; PMCID: PMC3086629.
      Citations: 769     Fields:    Translation:Humans
    122. Watts DH, Huang S, Cohn SE, Smith L, Hitti J. Repeat pregnancies among HIV-infected women enrolled in clinical trial PACTG1022. J Acquir Immune Defic Syndr. 2009 Jun 01; 51(2):231-3. PMID: 19465826; PMCID: PMC2766524.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    123. McComsey GA, Kang M, Ross AC, Lebrecht D, Livingston E, Melvin A, Hitti J, Cohn SE, Walker UA, AIDS Clinical Trials Group A5084. Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. HIV Clin Trials. 2008 Mar-Apr; 9(2):126-36. PMID: 18474497; PMCID: PMC3895476.
      Citations: 21     Fields:    Translation:HumansCells
    124. Livingston EG, Cohn SE, Yang Y, Watts HD, Bardeguez AD, Jones TB, Smith LM, Umbleja T, McComsey GA. Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy. Obstet Gynecol. 2007 Aug; 110(2 Pt 1):391-7. PMID: 17666616.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    125. Koletar SL, Williams PL, Wu J, McCutchan JA, Cohn SE, Murphy RL, Lederman HM, Currier JS, AIDS Clinical Trials Group 362 Study Team. Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. Clin Infect Dis. 2004 Nov 15; 39(10):1500-6. PMID: 15546087.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    126. Lederman HM, Williams PL, Wu JW, Evans TG, Cohn SE, McCutchan JA, Koletar SL, Hafner R, Connick E, Valentine FT, McElrath MJ, Roberts NJ, Currier JS, AIDS Clinical Trials Group 889 Study Team. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis. 2003 Dec 15; 188(12):1794-803. PMID: 14673757.
      Citations: 35     Fields:    Translation:HumansCellsCTClinical Trials
    Cohn's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (411)
    Co-Authors (38)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors